Accuracy and complexities of using automated clinical data for capturing chemotherapy administrations: Implications for future research

Medical Care

Volumn 47, Issue 10, 2009, Pages 1091-1097

  Bowles, Erin J Aiello ^a   Tuzzio, Leah ^a   Ritzwoller, Debra P ^b   Williams, Andrew E ^c   Ross, Tyler ^a   Wagner, Edward H ^a   Neslund Dudas, Christine ^d   Altschuler, Andrea ^e   Quinn, Virginia ^f   Hornbrook, Mark ^g   Nekhlyudov, Larissa ^h  

^a CENTER FOR HEALTH STUDIES   (United States)

^b KAISER PERMANENTE   (United States)

^c KAISER PERMANENTE   (United States)

^d HENRY FORD HEALTH SYSTEM   (United States)

^e DIVISION OF RESEARCH   (United States)

^f Kaiser Permanente Southern California ^*  (United States)

^g Center for Health Research   (United States)

^h HARVARD PILGRIM HEALTH CARE   (United States)

Author keywords

Chemotherapy; Medical chart; Ovarian cancer; Tumor registry; Validation of automated clinical data

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; HEALTH CARE; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; OVARY CANCER;

AGED; ANTINEOPLASTIC AGENTS; CONFIDENCE INTERVALS; CURRENT PROCEDURAL TERMINOLOGY; DATA COLLECTION; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; OVARIAN NEOPLASMS; REGISTRIES; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 70349690186     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181a7e569     Document Type: Article

References (13)

1. Ries LAG, Krapcho M, Mariotto A, eds. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute.
2. NCI Plans and Priorities: Cancer Survivorship. Available at: http:// plan2004.cancer.gov/public/survivor.htm. Accessed July 23, 2008.
3. Geiger AM, Buist DS, Greene SM, et al. Survivorship research based in integrated healthcare delivery systems: the Cancer Research Network. Cancer. 2008;112:2617-2626.
4. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40:IV-55-IV-61.
5. Du XL, Key CR, Dickie L, et al. Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews. J Clin Epidemiol. 2006;59:53-60.
6. Cress RD, Zaslavsky AM, West DW, et al. Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries. Med Care. 2003;41:1006-1012.
7. Roetzheim RG, Chirikos TN, Wells KJ, et al. Managed care and cancer outcomes for Medicare beneficiaries with disabilities. Am J Manag Care. 2008;14:287-296.
8. Du XL, Key CR, Dickie L, et al. External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care. 2006;44:124-131.
9. Wagner EH, Greene SM, Hart G, et al. Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr. 2005;35:3-11.
10. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV-3- IV-18.
11. Hornbrook MC, Hart G, Ellis JL, et al. Building a virtual cancer research organization. J Natl Cancer Inst Monogr. 2005;35:12-25.
12. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
13. Ramsey SD, Martins RG, Blough DK, et al. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care. 2008; 14:297-306